MyFinsight
Home
Blog
About
Maturities of marketable
securities
$84,000K
(-35.52%↓ Y/Y)
Proceeds from exercise of
common stock options
$2,194K
(64.96%↑ Y/Y)
Proceeds from espp
purchases
$254K
Net cash (used in)
provided by investing...
$29,210K
(-0.01%↓ Y/Y)
Net cash provided by
financing activities
$2,321K
(74.51%↑ Y/Y)
Canceled cashflow
$54,790K
Canceled cashflow
$127K
Net decrease in cash
and cash...
$8,909K
(193.09%↑ Y/Y)
Canceled cashflow
$22,622K
Purchases of marketable
securities
$53,889K
(-49.32%↓ Y/Y)
Purchases of property and
equipment
$901K
(22.25%↑ Y/Y)
Accrued expenses
$11,197K
(3571.15%↑ Y/Y)
Stock-based compensation
expense
$6,064K
(60.59%↑ Y/Y)
Operating lease
liabilities
$2,786K
(481.63%↑ Y/Y)
Prepaid expenses and
other current assets
-$258K
(69.75%↑ Y/Y)
Non cash operating
lease expense
$120K
(73.91%↑ Y/Y)
Depreciation expense
$79K
(-21.00%↓ Y/Y)
Other assets
-$43K
Payments related to
offering costs
$127K
Net cash used in
operating activities
-$22,622K
(43.60%↑ Y/Y)
Canceled cashflow
$20,547K
Net loss
-$37,095K
(14.31%↑ Y/Y)
Accounts payable
-$3,227K
(-821.92%↓ Y/Y)
Operating lease
right-of-use assets
$2,426K
(328.62%↑ Y/Y)
Accretion and
amortization of marketable...
$421K
(-81.87%↓ Y/Y)
Back
Back
Cash Flow
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)
source: myfinsight.com